Skip to content

Quality and in vivo clinical assessment of the effectiveness and toxicity of Ursus -1 mixture: an anti-peptic ulcer herbal product in Ghana

Quality and in vivo clinical assessment of the effectiveness and toxicity of Ursus -1 mixture: an anti-peptic ulcer herbal product in Ghana

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
PACTR
Registry ID
PACTR202510734066201
Enrollment
30
Registered
2025-10-20
Start date
2024-01-03
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Peptic Ulcer Disease

Interventions

Ursus 1 Mixture

Sponsors

Magdalene Oti
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Males and females • Adult ages 18 years and above • Patients with the following presentations: o Epigatric pain o Heart burn o Nausea and vomiting o Abdominal discomfort o Indigestion o Gastritis • Presence of H.pylori on laboratory investigation • No history of ingestion of any antibiotics, NSAIDS and anti-ulcer product within the past 30 days • Patients able and willing to come back for follow up • Easy access to the health facility

Exclusion criteria

Exclusion criteria: • Age less than 18 years • Complications of peptic ulcer including haemorrhage • Chronic ingestion of NSAIDs • Disturbed Gastrointestinal physiology (vagotomy, gastric surgery, Zollinger-Ellison syndrome) • Breastfeeding or pregnant females • Haemoglobin below 8g/dl • Individuals on other medication for PUD. (Eg. Antibiotics, proton pump inhibitor, etc) • Patients with concomitant diseases e.g. Diabetes, hypertension, liver and/or renal disease(s) • Patients on using other medications that may interact with the study (e.g., Warfarin, anti- epileptics) • Presence of clinically significant abnormal laboratory results during screening • Use of any recreational drugs or having a history of drug dependence • Inability to come for stipulated follow-up visits

Design outcomes

Primary

MeasureTime frame
Assessment of effectiveness based on improvement of frequency of occurrence of symptoms

Secondary

MeasureTime frame
Clearance of H.pylori

Countries

Ghana

Contacts

Public ContactJohn Appiahpoku

Kwame Nkrumah University of Science and Technology

chrpe@knust.edu.gh00233205453785

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026